Mark Cuban Discusses DEI and Healthcare Reform Vision for 2024
In recent times, American entrepreneur Mark Cuban has taken a bold step into the healthcare industry with his venture, Cost Plus Drugs. This innovative company is challenging the status quo by offering radical transparency in medication pricing, aiming to save patients hundreds of millions of dollars.
However, Cuban's involvement goes beyond just disrupting the pharmaceutical market. He is also aiming to rebuild trust in American healthcare, an industry notoriously opaque and fundamentally broken due to a lack of transparency.
Traditional Pharmacy Benefit Managers (PBMs) have been criticised for prioritising profits over transparency, operating behind a veil of secrecy enforced by non-disclosure agreements. As a result, companies often overpay for medications through traditional PBMs, with benefits consultants directing them to providers offering the highest commissions.
This situation is further exacerbated when we consider the example of a biosimilar of Humira, America's highest-revenue drug. Despite being cheaper through Cost Plus Drugs, it is blocked by major PBMs due to the lack of rebates. This cartel-like situation is squeezing community pharmacies out of business.
Cost Plus Drugs operates outside this broken system, refusing to work with major PBMs. This move could potentially pave the way for transparency across other aspects of the industry, setting a precedent for change.
In the corporate world, the focus on Diversity, Equity, and Inclusion (DEI) is increasingly becoming a business decision made by leadership based on their assessment of what serves company interests. While Mark Cuban has not publicly discussed the specific business benefits of DEI programs, he does emphasise the importance of equity in company culture. He advocates for ensuring that employees "own part of the company" and share in its success, believing that sharing rewards leads to a more motivated and engaged workforce.
Research and commentary from other business leaders and researchers highlight the advantages of DEI programs. These typically include improved talent attraction and retention, enhanced innovation, stronger customer relationships, and better financial performance. Companies that implement DEI well can gain competitive advantages through broader access to qualified candidates.
However, those that implement DEI poorly will lose talent and struggle to execute their business plans. The notion that DEI programs systematically discriminate against certain groups is more narrative than reality. The market will likely evolve towards multiple AI models serving different needs rather than a single dominant approach.
In conclusion, Mark Cuban's Cost Plus Drugs initiative is a significant step towards bringing transparency to the healthcare industry. While there is no direct evidence that Cuban has publicly discussed the specific business benefits of DEI programs in corporate settings, his emphasis on equitable reward sharing aligns with broader DEI objectives. The future belongs to organisations that can implement DEI thoughtfully as part of a broader talent strategy while maintaining focus on business fundamentals.
Finance is a critical aspect that Mark Cuban is considering in his healthcare venture, Cost Plus Drugs, as he aims to save patients millions of dollars by disrupting the pharmaceutical market. Moreover, in the corporate world, his emphasis on equitable reward sharing among employees aligns with the broader objectives of Diversity, Equity, and Inclusion (DEI) programs, which are increasingly becoming a business decision based on financial performance and overall company success.
